Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06120361 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Swedish BioFINDER - Primary Care Study

Study acronym: ADetect
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Status, Oversight, Contacts/Locations, Referencesv5
  2. 2 versions Re-verified since Nov 30, 2024, no change to tracked fieldsv3-v4
  3. Primary endpoint revisedv2 Show 4 more changesShow less
    • Interventions: Different cognitive tests (Diagnostic Test), MRI and CT of the brain (Diagnostic Test), Plasma APS 2 score (Diagnostic Test), Plasma… to Different cognitive tests (Diagnostic Test), MRI and CT of the brain (Diagnostic Test), Plasma APS 2 score (Diagnostic Test), Plasma…
    • Secondary endpoints revised (6)
    • Study description expanded, about 40 words
    • Eligibility criteria expanded, about 1 word
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics. The investigators will strive to recruit diverse and representative populations of patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and mild dementia. The specific aims of the study are to: 1. Improve the detection of mild cognitive impairment (MCI) and dementia in primary care. 2. Develop and evaluate cognitive tests, blood-based biomarkers and brain imaging methods that are suitable for accurate and early diagnosis of Alzheimer's disease (AD) in primary care. 3. To prospectively validate plasma AD biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in primary care. 4. Determine whether blood AD biomarkers improve patient management in primary care.
Trial Details
NCT Number NCT06120361
Lead Sponsor Skane University Hospital
Collaborators: Lund University
Conditions
(from sponsor)		 Mild Dementia, Mild Cognitive Impairment, SCD, Alzheimer Disease, Lewy Body Disease, Frontotemporal Degeneration, Vascular Dementia
Related terms Alzheimer Disease, Cognitive Dysfunction, Dementia, Vascular, Disease, Lewy Body Disease
Enrollment 1,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov